ECSP077351A - PRODUCCIÓN DE a-BETA - Google Patents
PRODUCCIÓN DE a-BETAInfo
- Publication number
- ECSP077351A ECSP077351A EC2007007351A ECSP077351A ECSP077351A EC SP077351 A ECSP077351 A EC SP077351A EC 2007007351 A EC2007007351 A EC 2007007351A EC SP077351 A ECSP077351 A EC SP077351A EC SP077351 A ECSP077351 A EC SP077351A
- Authority
- EC
- Ecuador
- Prior art keywords
- accumulated
- culture
- amino acids
- molar ratio
- glutamine
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 230000007423 decrease Effects 0.000 abstract 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 230000001186 cumulative effect Effects 0.000 abstract 1
- 229910001410 inorganic ion Inorganic materials 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/04—Plant cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se provee un sistema mejorado para la producción a gran escala de proteínas y a-Beta en cultivo de células, en particular, en medios caracterizados por una o más de las siguientes características: 1) una concentración acumulada de aminoácidos mayor que aproximadamente 70 mM; 2) una relación molar de glutamina acumulada a asparagina acumulada inferior a aproximadamente 2; 3) una relación molar de glutamina acumulada a aminoácidos totales acumulados inferior a aproximadamente 0,2; 4) una relación molar de ion inorgánico acumulado a aminoácidos totales acumulados de entre alrededor de 0,4 y 1; o 5) una concentración combinada de glutamina acumulada y asparagina acumulada de entre aproximadamente 16 y 36 mM. El uso de dicho sistema permite altos niveles de producción de a-Beta, y disminuye la acumulación de ciertos factores indeseables, tales como amonio y lactato. Adicionalmente, se proveen métodos de cultivo que incluyen un cambio de temperatura, que habitualmente comprende una disminución en la temperatura cuando el cultivo ha alcanzado alrededor de 20%-80% de su densidad celular máxima. Alternativa o adicionalmente, la presente invención provee métodos tales que, después de alcanzar un pico, los niveles de lactato y amonio en el cultivo disminuyen con el transcurso del tiempo
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60493604P | 2004-08-27 | 2004-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP077351A true ECSP077351A (es) | 2008-03-26 |
Family
ID=35500647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2007007351A ECSP077351A (es) | 2004-08-27 | 2007-03-27 | PRODUCCIÓN DE a-BETA |
Country Status (27)
Country | Link |
---|---|
US (1) | US7335491B2 (es) |
EP (2) | EP1781803B1 (es) |
JP (3) | JP2008511328A (es) |
KR (1) | KR100998857B1 (es) |
CN (1) | CN101048512B (es) |
AR (1) | AR050471A1 (es) |
AU (1) | AU2005280090A1 (es) |
BR (1) | BRPI0514680A (es) |
CA (1) | CA2578137C (es) |
CR (1) | CR8996A (es) |
EC (1) | ECSP077351A (es) |
EG (1) | EG25848A (es) |
ES (1) | ES2599103T3 (es) |
HN (1) | HN2005000486A (es) |
IL (1) | IL181587A (es) |
MX (1) | MX2007002382A (es) |
MY (1) | MY146097A (es) |
NO (1) | NO20071571L (es) |
NZ (1) | NZ591233A (es) |
PE (2) | PE20060715A1 (es) |
RU (1) | RU2418858C2 (es) |
SG (1) | SG155250A1 (es) |
SV (1) | SV2006002212A (es) |
TW (1) | TWI374935B (es) |
UA (1) | UA89644C2 (es) |
WO (1) | WO2006026408A2 (es) |
ZA (1) | ZA200702487B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
CN101432302A (zh) | 2005-11-30 | 2009-05-13 | 艾博特公司 | 抗-Aβ球聚体抗体,其抗原结合部分,相应的杂交瘤、核酸、载体、宿主细胞,生产所述抗体的方法,包含所述抗体的组合物,所述抗体的应用以及使用所述抗体的方法 |
CA2631195C (en) | 2005-11-30 | 2016-04-05 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
PT2361638E (pt) * | 2005-12-12 | 2014-04-17 | Ac Immune Sa | Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas |
PT2495307T (pt) * | 2006-07-13 | 2018-05-10 | Wyeth Llc | Produção do fator ix de coagulação com padrão melhorado de glicosilação |
EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
JP5401319B2 (ja) * | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | 細胞培養における解糖阻害物質 |
KR101523782B1 (ko) | 2006-11-08 | 2015-05-28 | 와이어쓰 엘엘씨 | 세포 배양을 위한 합리적으로 설계된 배지 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (en) * | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
NZ579310A (en) | 2007-03-01 | 2012-03-30 | Probiodrug Ag | Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof |
US9012180B2 (en) * | 2007-03-02 | 2015-04-21 | Wyeth Llc | Use of copper and glutamate in cell culture for production of polypeptides |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
KR101574355B1 (ko) | 2007-04-26 | 2015-12-11 | 추가이 세이야쿠 가부시키가이샤 | 고농도 아미노산 함유 배지를 사용한 세포의 배양 방법 |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
PE20090766A1 (es) * | 2007-06-12 | 2009-07-09 | Ac Immune Sa | Anticuerpo igg1 humanizado |
CA2701793C (en) * | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
PL2310523T3 (pl) * | 2008-04-17 | 2015-10-30 | Wyeth Llc | Sposoby zwiększonego wytwarzania białek morfogenetycznych kości |
MX2011002638A (es) | 2008-09-15 | 2011-04-05 | Genentech Inc | Composiciones y metodos para regular osmolaridad celular. |
KR20180114966A (ko) | 2009-08-11 | 2018-10-19 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
US8470552B2 (en) * | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
US9428727B2 (en) | 2010-04-26 | 2016-08-30 | Novartis Ag | Cell culture medium |
JP6113653B2 (ja) | 2010-04-26 | 2017-04-12 | ノバルティス アーゲー | 改良型細胞培養培地 |
MX2012012528A (es) | 2010-04-26 | 2012-11-23 | Novartis Ag | Proceso de cultivo celular mejorado. |
SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
CA2807607A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
FI20115704L (fi) | 2011-07-01 | 2013-01-02 | Teknologian Tutkimuskeskus Vtt Oy | Vierasproteiinien tuoton parantaminen |
CN103827292B (zh) * | 2011-07-01 | 2018-01-26 | 安姆根有限公司 | 哺乳动物细胞培养 |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
HUE039551T2 (hu) | 2013-10-11 | 2019-01-28 | Regeneron Pharma | Metabolikusan optimalizált sejttenyészet |
DE102017203908B3 (de) * | 2017-03-09 | 2018-05-30 | Evonik Technochemie Gmbh | Kulturmedium, umfassend Oligopeptide |
EP3638772B1 (en) * | 2017-06-16 | 2024-08-28 | Katholieke Universiteit Leuven | Cell culture media for differentiation of stem cells into hepatocytes |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
RS65472B1 (sr) * | 2018-07-03 | 2024-05-31 | Bristol Myers Squibb Co | Postupak proizvodnje rekombinantnih proteina |
MY193349A (en) | 2019-12-06 | 2022-10-06 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
EP4107249A1 (en) * | 2020-02-18 | 2022-12-28 | Boehringer Ingelheim International GmbH | Mammalian cell culture processes |
BR112023001061A2 (pt) | 2020-07-23 | 2023-04-04 | Othair Prothena Ltd | Anticorpos antiabeta |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
WO1990003430A1 (en) * | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US6291159B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
KR0185192B1 (ko) | 1989-10-05 | 1999-04-01 | 제임스 더블유. 데이비 | 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 |
US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
US5156964A (en) * | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
JPH059735A (ja) * | 1991-07-09 | 1993-01-19 | Kobe Steel Ltd | ダイヤモンドの気相合成方法 |
GB9118664D0 (en) * | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片 |
US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US5856179A (en) * | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
CA2253557A1 (en) * | 1996-05-08 | 1997-11-13 | Louis Martin Renzetti | Treatment of asthma with tnfr-ig |
US6156570A (en) * | 1997-03-20 | 2000-12-05 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
US20020012991A1 (en) | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
DE60229051D1 (de) | 2001-04-30 | 2008-11-06 | Lilly Co Eli | Humanisierte antikörper |
DE60230736D1 (de) | 2001-04-30 | 2009-02-26 | Lilly Co Eli | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
WO2002101019A2 (en) | 2001-06-13 | 2002-12-19 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
PT3127553T (pt) | 2002-05-02 | 2022-01-24 | Wyeth Holdings Llc | Conjugados de derivado da caliqueamicina - transportador |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
-
2005
- 2005-08-25 TW TW094129074A patent/TWI374935B/zh not_active IP Right Cessation
- 2005-08-25 US US11/213,317 patent/US7335491B2/en not_active Expired - Fee Related
- 2005-08-26 MX MX2007002382A patent/MX2007002382A/es active IP Right Grant
- 2005-08-26 WO PCT/US2005/030364 patent/WO2006026408A2/en active Application Filing
- 2005-08-26 ES ES05791655.3T patent/ES2599103T3/es active Active
- 2005-08-26 PE PE2005000986A patent/PE20060715A1/es not_active Application Discontinuation
- 2005-08-26 CN CN2005800368972A patent/CN101048512B/zh not_active Expired - Fee Related
- 2005-08-26 SV SV2005002212A patent/SV2006002212A/es unknown
- 2005-08-26 RU RU2007108718/10A patent/RU2418858C2/ru not_active IP Right Cessation
- 2005-08-26 HN HN2005000486A patent/HN2005000486A/es unknown
- 2005-08-26 MY MYPI20054022A patent/MY146097A/en unknown
- 2005-08-26 AU AU2005280090A patent/AU2005280090A1/en not_active Abandoned
- 2005-08-26 SG SG200905720-9A patent/SG155250A1/en unknown
- 2005-08-26 PE PE2009001268A patent/PE20100147A1/es not_active Application Discontinuation
- 2005-08-26 JP JP2007530148A patent/JP2008511328A/ja active Pending
- 2005-08-26 EP EP05791655.3A patent/EP1781803B1/en active Active
- 2005-08-26 CA CA2578137A patent/CA2578137C/en not_active Expired - Fee Related
- 2005-08-26 AR ARP050103595A patent/AR050471A1/es not_active Application Discontinuation
- 2005-08-26 BR BRPI0514680-1A patent/BRPI0514680A/pt not_active Application Discontinuation
- 2005-08-26 NZ NZ591233A patent/NZ591233A/xx not_active IP Right Cessation
- 2005-08-26 UA UAA200703284A patent/UA89644C2/ru unknown
- 2005-08-26 EP EP10184494A patent/EP2348126A3/en not_active Withdrawn
- 2005-08-26 KR KR1020077004809A patent/KR100998857B1/ko not_active IP Right Cessation
-
2007
- 2007-02-27 EG EGNA2007000224 patent/EG25848A/xx active
- 2007-02-27 IL IL181587A patent/IL181587A/en not_active IP Right Cessation
- 2007-03-16 CR CR8996A patent/CR8996A/es unknown
- 2007-03-26 NO NO20071571A patent/NO20071571L/no not_active Application Discontinuation
- 2007-03-26 ZA ZA2007/02487A patent/ZA200702487B/en unknown
- 2007-03-27 EC EC2007007351A patent/ECSP077351A/es unknown
-
2012
- 2012-02-17 JP JP2012033105A patent/JP2012095671A/ja active Pending
-
2015
- 2015-04-01 JP JP2015075425A patent/JP2015133980A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP077353A (es) | Producción de polipéptidos | |
ECSP077351A (es) | PRODUCCIÓN DE a-BETA | |
ECSP077354A (es) | PRODUCCIÓN DE TNFR-Ig | |
ES2570382T3 (es) | Composiciones y métodos para la producción de azúcares fermentables | |
AR076863A1 (es) | Aparato y metodo para reduccion de materia prima solida. | |
CL2018002140A1 (es) | Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos | |
AR051304A1 (es) | Proceso para preparar 4,5-dihidro-pirazolo (3,4) pirid-2-onas e intermediarios | |
EA201270224A1 (ru) | Среда для культивирования клеток для экспрессии белков adamts | |
GT200500330A (es) | Derivados de quinolina e isoquinolina 5-sustituidos, un prodecimiento para su preparacion y su uso como inhibidores de la inflamacion | |
EA202090067A2 (ru) | Способ получения рекомбинантного adamts13 в культуре клеток | |
DE602008006086D1 (de) | Zellenneuauswahl in einem drahtlosen kommunikationssystem | |
NI200800111A (es) | Método de producción proteica utilizando compuestos anti-senescencia | |
RS54073B1 (en) | STROMAL MATERIAL CELLS | |
AR090822A1 (es) | Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos | |
DK1851815T3 (da) | Fremgangsmåde til fremstilling af en brændselscellekatode | |
BR112015021993A8 (pt) | polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular | |
WO2016168890A8 (en) | Generation of muscle-lineage cells from stem cells | |
PA8779101A1 (es) | "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales" | |
BRPI0912164A2 (pt) | processo para a degradação de lignina. | |
WO2009155041A3 (en) | Method to modulate hematopoietic stem cell growth | |
BR112015013071A8 (pt) | solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida | |
WO2007030674A3 (en) | Use of nucleases to improve viability and enhance transgene expression in transfected cells | |
WO2007130664A3 (en) | Derivation of embryonic stem cells and embryo-derived cells | |
CO6390009A2 (es) | Reactor electrobioquimico | |
ATE540313T1 (de) | Identifizierung von keimbahnfähigen embryonischen stammzellen |